GlaxoSmithKline Presents Positive Efficacy Data Of Dostarlimab

(Alliance News) - GlaxoSmithKline PLC on Monday said results from the Garnet study showed durable ...

Alliance News 18 January, 2021 | 6:26PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GlaxoSmithKline PLC on Monday said results from the Garnet study showed durable responses across tumour types.

Glaxo said the study results showed a 38.7% objective response rate in patients with deficient mismatch repair advanced solid cancers who received the dostarlimab monoclonal antibody. Additionally, after a median follow-up of 12.4 months, the median duration of response had not yet been reached and responses were durable across tumour types.

The ongoing phase I Garnet trial is evaluating dostarlimab as monotherapy in patients with advanced solid tumours.

Senior Vice President and Head of Oncology R&D Axel Hoos said: "We are committed to finding new approaches to improve outcomes for patients with difficult to treat cancers who have limited treatment options today. These new results from the ongoing GARNET study demonstrate the potential for dostarlimab to help a broad range of patients with solid tumours that have a deficiency in DNA mismatch repair."

The stock closed down 0.9% at 1,400.74 pence on Monday in London.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,653.00 GBX 0.76

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures